Background Image
Table of Contents Table of Contents
Previous Page  151 / 1498 Next Page
Information
Show Menu
Previous Page 151 / 1498 Next Page
Page Background

Duration of Response

in

90

Y Ibritumomab Tiuxetan Trials

Phase I-II

Phase II

Phase III

n

= 51

n

= 30

n

= 73

Overall Response, %

73

83

80

Median DR, months

11.7

11.5

13.9

CR/CRu, %

29*

47

34

Median DR, months

28*

23

23

Ongoing CR/CRu, %

19

14

32

Median DR, months

62.1

41.2

42.2

Range

60+ to 66+

40+ to 42+

33+ to 48+

Gordon et al. Blood 2004.

*Patients with CR only.